Sangamo Therapeutics misses top-line and bottom-line estimates; reaffirms FY25 outlook
Source: SeekingAlpha
2025-05-13 01:00:50 ET
More on Sangamo Therapeutics
- Sangamo Therapeutics, Inc. (SGMO) Q1 2025 Earnings Call Transcript
- Sangamo Therapeutics, Inc. 2025 Q1 - Results - Earnings Call Presentation
- Sangamo Therapeutics: Scope Goes Beyond That Of Recent Eli Lilly Licensing Deal
- Sangamo Therapeutics Q1 2025 Earnings Preview
- Eli Lilly to leverage Sangamo capsid technology for CNS disease therapies
Read the full article on Seeking Alpha
For further details see:
Sangamo Therapeutics misses top-line and bottom-line estimates; reaffirms FY25 outlook
Sangamo Therapeutics Inc.
NASDAQ: SGMO
SGMO Trading
-5.43% G/L:
$0.38 Last:
2,205,995 Volume:
$0.3955 Open:
SGMO Latest News
March 09, 2026 08:05:00 am
Sangamo Therapeutics Advances Rolling Submission of BLA to U.S. FDA for ST-920 in Fabry Disease
February 03, 2026 04:05:00 pm
Sangamo Therapeutics Presents Detailed Data from Registrational STAAR Study in Fabry Disease at WORLDSymposium(TM) 2026
SGMO Stock Data
$133,083,570
322,698,215
1.31%
45
N/A
Biotechnology & Life Sciences
Healthcare
US
Richmond
